[Asia Economy Reporter Chunhee Lee] Hwang Tae-soon, CEO of Theragen Bio, has been reappointed as the 4th president of the Genome Companies Council under the Korea Bio Association.
The Genome Companies Council held its regular general meeting on the 30th of last month at the headquarters of LabGenomics in Pangyo, Seongnam, Gyeonggi Province, where this decision was made. Established in 2015, the council currently has 26 member companies.
CEO Hwang, who served as the 3rd president of the council from July 2019 for two years, will lead the council for another two years until June 2023 through this reappointment.
Shin Sang-chul, CEO of EDGC (Eone Diagnomics Genome Center), who serves as vice president, along with Lee Jong-eun, CEO of DNA Link; Lee Soo-kang, CEO of Macrogen; Jin Seung-hyun, CEO of LabGenomics; Choi Dae-chul, CEO of Ngen Bio; and Kwon Soon-jae, CEO of AccuGene, five operating committee members, were also reappointed.
During their tenure, President Hwang and the 3rd executive team successfully led projects such as the Ministry of Health and Welfare’s pilot project for the DTC (Direct-to-Consumer) genetic testing certification system. They also worked to identify regulations and promote innovation in the bio sector, including amendments to the Bioethics Act.
Through this reappointment of executives, the Genome Companies Council plans to take a more active role in addressing current issues in the genome industry, such as expanding DTC genetic testing, allowing clinical NGS (Next-Generation Sequencing) testing in non-medical institutions, and building the national bio big data platform (K-DNA).
The event was attended by many industry representatives, including the president, vice president, and five operating committee company CEOs, as well as Shin Dong-jik, CEO of Medigen Human Care; Ki Chang-seok, CEO of GC Green Cross Genome; Oh Sang-hoon, CEO of Cha Biotech; Kim Dong-ho, CEO of LAS; and Shin Jae-guk, CEO of SP Med.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
